Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human Phase 1/2 Trial to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of SOT106 in Patients With LRRC15-positive Advanced Unresectable or Metastatic Osteosarcoma and Soft Tissue Sarcoma

NCT07801222 is registered in ClinicalTrials.gov with SOTIO Biotech a.s. as lead sponsor.

NCT NCT07801222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07801222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human Phase 1/2 Trial to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of SOT106 in Patients With LRRC15-positive Advanced Unresectable or Metastatic Osteosarcoma and Soft Tissue Sarcoma
Lead sponsor
SOTIO Biotech a.s.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
May 21, 2030
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteosarcoma metastatic, osteosarcoma, advanced, soft tissue sarcoma (sts)